Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: a retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
Dunn TJ, Zhu Y, Gronroos NN, et al.
Diabetes Res Clin Pract. 2025:112162.
Leggi